Market Signal Briefing

-

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Eagle Pharmaceuticals, Inc. (OTCPK: EGRX) breached their fiduciary duties to shareholders.

If you currently own Eagle stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected]. Our firm would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Why Your Participation Matters:

Shareholder involvement can help improve a company’s policies, practices, and oversight mechanisms to create a more transparent, accountable, and effectively managed organization, which can enhance shareholder value.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

More News From Halper Sadeh LLC

Back to Newsroom

The photonics chipmaker still needs to clear a lot of technical hurdles.

Quantum Computing (QUBT 5.45%), also known as QCI, made the jump from the over-the-counter market to the Nasdaq on July 15, 2021. It opened at $6.60 per share that day, but it eventually sank to a record low of $0.42 on July 1, 2024.

But today, QCI trades at about $12 -- so a $1,000 investment at its all-time low would have grown to nearly $28,600 in just over a year. Let's see why this emerging quantum computing stock is attracting so much attention and where it might be headed over the next year.

Image source: Getty Images.

Understanding the quantum computing market
Standard computers still store zeros and ones separately in binary bits. Quantum computers can store those zeros and ones simultaneously in qubits, which allows them to process more data and certain computing tasks at a much faster rate than their classical counterparts.

But for now, quantum computers are still much larger, pricier, and consume more power than standard computers. They also tend to make more mistakes. That's why they're still mainly used for niche government and research projects instead of mainstream computing applications.

Today's Change

(

-5.45

%) $

-0.74

Current Price

$

12.84

To address those issues, quantum computing companies are trying to make those systems smaller, cheaper, and more power-efficient. Yet there isn't a clear consensus regarding how to achieve those goals.

Most of the early movers in the quantum computing market -- including IBM (IBM 0.02%) and Rigetti Computing (RGTI 6.49%) -- accelerate electrons through "superconducting loops" to process data. These systems are easier to manufacture, but they're big and expensive to operate because they need to be cryogenically refrigerated.

Other companies -- most notably IonQ (IONQ 3.78%) -- "trap" ions and manipulate them with tiny lasers to process that data. These smaller systems don't need to be refrigerated, but they can also be expensive to operate because their delicate lasers need to be constantly recalibrated.

What sets QCI apart from its competitors?
QCI doesn't dabble with electrons and ions. Instead, it develops photonic quantum chips -- which process data by beaming light through chips, fibers, and optical circuits. These chips can function at room temperature and can be easily manufactured by conventional chip fabricators.

In theory, QCI's photonic chips can be cheaper, more scalable, and require less maintenance than trapped ion systems. But for now, they're still more expensive to manufacture, produce more errors, and must be paired with big external optical systems.

QCI opened its first foundry this May and finally started shipping its first chips, but it only generated $484,000 in revenue in the first nine months of 2025. Most of that revenue came from its professional service contracts with commercial and government customers, but it also started to recognize some revenue from its cloud-based Dirac-3 quantum-as-a-service platform this year.

For the full year, analysts expect it to generate $777,000 in revenue with a net loss of nearly $24 million. With a market cap of $2.7 billion, QCI stock trades at 3,481 times this year's sales. By comparison, IonQ and Rigetti trade at 159 times and 1,134 times this year's sales, respectively. All three of these quantum computing stocks are speculative -- but QCI still seems the most overvalued relative to its near-term growth potential.

What are QCI's longer-term catalysts?
QCI is currently planning the construction of its second fab, which it aims to start building within the next three years. In the meantime, it expects to refine its manufacturing processes, ramp up its small-batch production, expand its workforce, and demonstrate its performance capabilities at its first fab.

Yet QCI doesn't expect to mass-produce its chips until its second fab opens. So over the next year, most of its modest revenue will still come from its professional service contracts and cloud-based services. It will also likely need to raise more cash by issuing more debt and secondary offerings. For 2026, analysts expect QCI's revenue to surge 169% to $2.1 million as its net loss widens to $40.5 million.

Where will QCI's stock be in a year?
QCI has a lot of growth potential, but it still has plenty of hurdles to clear. It must scale up its business, reduce its production costs, and prove that its photonics chips are actually cheaper and more scalable than electron or ion-based systems.

It faces an uphill battle against those entrenched players, and it could easily run out of money before it reaches the mass production stage. It also faces competition from smaller photonics companies like Xanadu and PsiQuantum.

QCI's stock might go through some wild swings over the next year, but I don't think those gains will be sustainable. Instead, I believe it will either trade sideways or slip lower unless it demonstrates some big technological breakthroughs or lands some huge new contracts.

This hedge fund just made a bold bet on a behavioral-health giant in the middle of a reset—here’s what they may be seeing.

On November 14, New York City-based Engine Capital Management disclosed a new position in Acadia Healthcare (ACHC +5.74%), acquiring 2.6 million shares valued at $64 million.

What HappenedAccording to a Securities and Exchange Commission (SEC) filing dated November 14, Engine Capital Management initiated a new position in Acadia Healthcare, acquiring nearly 2.6 million shares. The stake was valued at $64 million at the end of the third quarter. This transaction brought the fund’s total reported U.S. equity positions to 27.

What Else to KnowEngine Capital’s new position in ACHC represents 7.6% of its reportable assets under management as of September 30.

Top holdings after the filing: 

NYSE: AVTR: $246.1 million (29.2% of AUM)NYSE: NATL: $94.7 million (11.2% of AUM)NASDAQ: LNW: $80.9 million (9.6% of AUM)NASDAQ: ACHC: $64.0 million (7.6% of AUM)NASDAQ: OFIX: $62.3 million (7.4% of AUM)As of Friday, shares of Acadia Healthcare were priced at $15.47, down 63% over the past year and far underperforming the S&P 500, which is up 13% in the same period.

Company OverviewMetricValueRevenue (TTM)$3.3 billionNet income (TTM)$107.4 millionMarket capitalization$1.4 billionPrice (as of market close Friday)$15.47Company SnapshotAcadia Healthcare operates hundreds of behavioral healthcare facilities across the United States and Puerto Rico.The company focuses on inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers, and outpatient clinics.It serves a diverse patient base seeking mental health and addiction treatment services.Acadia Healthcare is a leading provider of behavioral healthcare services, leveraging its broad network to address a wide range of mental health and addiction needs. Its scale and specialized care offerings position it as a key player in the behavioral health sector.

Foolish TakeA sharp move into Acadia Healthcare matters because it shows a fund leaning into a sector facing short-term turbulence but long-term demand tailwinds. Behavioral health remains one of the few healthcare categories with structurally rising need, and Acadia’s recent results hint at stabilization even as near-term profitability is under pressure. For long-term investors, this kind of contrarian build-up can signal that current valuation weakness may not reflect the company’s full earnings power once volumes recover and expansion projects mature.

Engine Capital’s new $64 million position comes as Acadia reported 4.4% year-over-year revenue growth to $851.6 million and continued momentum in same-facility admissions, up 3.3%. But the company also lowered full-year revenue, EBITDA, and EPS guidance amid payor scrutiny, Medicaid softness, and higher liability costs. Adjusted EBITDA fell to $173 million from $194 million a year earlier.

Still, management is cutting 2026 capex by at least $300 million and pushing toward positive free cash flow—moves that could materially improve returns once bed additions start contributing. So what might be worth taking away? Demand is durable, margins are fixable, and the stock’s 63% drop over 12 months may have already priced in much of the pain.

GlossaryAssets under management (AUM): The total market value of investments managed by a fund or investment firm.

Reportable U.S. equity assets: U.S. stock holdings that an investment manager must disclose in regulatory filings.

Position: The amount of a particular security or asset held by an investor or fund.

Stake: The ownership interest or share held in a company by an investor or fund.

Holding: A security or asset owned within an investment portfolio.

Initiated a new position: When an investor or fund buys shares of a company for the first time.

Behavioral healthcare services: Medical services focused on treating mental health and substance use disorders.

Inpatient psychiatric hospitals: Facilities where patients stay overnight for intensive mental health treatment.

Residential treatment centers: Live-in healthcare facilities providing therapy and support for behavioral or addiction issues.

Outpatient clinics: Healthcare centers where patients receive treatment without staying overnight.

Market capitalization: The total value of a company's outstanding shares, calculated as share price times shares outstanding.

TTM: The 12-month period ending with the most recent quarterly report.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of VOO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Why would a fund step away from a stock that’s quietly building one of the strongest backlogs in federal contracting?

On November 14, New York City-based Engine Capital Management disclosed that it sold out its entire position in Amentum Holdings (AMTM 1.26%), a move representing an estimated $15 million change in value.

What HappenedAccording to its SEC filing dated November 14, Engine Capital Management, LP reported a complete sale of its Amentum Holdings position during the third quarter. The fund eliminated 635,255 shares, an estimated $15 million transaction based on quarterly average pricing.

What Else to KnowTop holdings after the filing: 

NYSE: AVTR: $246.1 million (29.2% of AUM)NYSE: NATL: $94.7 million (11.2% of AUM)NASDAQ: LNW: $80.9 million (9.6% of AUM)NASDAQ: ACHC: $64.0 million (7.6% of AUM)NASDAQ: OFIX: $62.3 million (7.4% of AUM)As of Friday, shares of Amentum Holdings were priced at $28.88, up 26% over the past year and outperforming the S&P 500, which is up 13% in the same period.

Company OverviewMetricValuePrice (as of market close Friday)$28.88Market capitalization$7 billionRevenue (TTM)$14.4 billionNet income (TTM)$66 millionCompany SnapshotAmentum Holdings provides mission-critical services including test, training, and operations for missile defense, IT and engineering for defense and space, environmental remediation, and advanced cyber and intelligence solutions.The company generates revenue through long-term government and commercial contracts, focusing on technology-driven consulting, systems integration, and technical services.It serves U.S. government agencies, defense and intelligence clients, and energy sector organizations as primary customers.Amentum Holdings is a leading provider of technical and mission support services to government and commercial clients, with a focus on aerospace, defense, and intelligence sectors. The company leverages its scale and expertise in critical mission solutions and advanced cyber capabilities to address complex national security and infrastructure needs. It combines its deep technical know-how with a robust contract portfolio, positioning itself as a key partner for clients requiring high-reliability, technology-driven solutions.

Foolish TakeAmentum’s recent rally underscores why understanding a full exit like this matters for long-term investors: When a fund divests following a stretch of strengthening fundamentals, it can signal a shift in portfolio strategy rather than a judgment on the business itself. The company just delivered a standout fourth quarter, posting $3.9 billion in revenue, $300 million in adjusted EBITDA, and $261 million in free cash flow, all while expanding backlog to a massive $47.1 billion and reducing its net leverage.

For investors, Amentum’s multi-year contract visibility, strong cash generation, and fiscal year 2026 guidance calling for up to $14.3 billion in revenue and as much as $575 million in free cash flow offer notable long-term appeal. The business is tied to mission-critical spending across defense, space, nuclear, and digital infrastructure—areas less sensitive to economic cycles. While the stock remains volatile since its public-market debut last September, the underlying growth trajectory appears intact.

Glossary13F reportable assets: Investment holdings that institutional investment managers must disclose quarterly to the Securities and Exchange Commission (SEC) if above a certain threshold.

Assets under management (AUM): The total market value of all investments managed by a fund or investment firm.

Stake: The ownership interest or investment a fund or individual holds in a particular company.

Quarterly average pricing: The average price of a security over a specific quarter, used for estimating transaction values.

Mission-critical services: Essential services that are vital to the core operations or security of an organization or client.

Systems integration: The process of combining different technology systems and software to function as a coordinated whole.

Technical services: Specialized support involving engineering, IT, or scientific expertise provided to clients.

Contract portfolio: The collection of active contracts a company holds with its clients, often indicating business stability and future revenue.

TTM: The 12-month period ending with the most recent quarterly report.

December 07, 2025 4:05 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - December 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Marex Group plc (NASDAQ: MRX) between May 16, 2024 and August 5, 2025, both dates inclusive (the "Class Period"), of the important December 8, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Marex securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Marex class action, go to https://rosenlegal.com/submit-form/?case_id=43100 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. If you wish to serve as lead plaintiff, you must move the Court no later than December 8, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, during the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Marex sold over-the-counter financial instruments to itself; (2) Marex had inconsistencies in its financial statements between its subsidiaries and related parties, including as to intercompany receivables and loans; (3) as a result of the foregoing, Marex's financial statements could not be relied upon; and (4) as a result of the foregoing, defendants' positive statements about Marex's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Marex class action, go to https://rosenlegal.com/submit-form/?case_id=43100 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277075

December 07, 2025 4:27 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - December 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.

SO WHAT: If you purchased MoonLake common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the MoonLake class action, go to https://rosenlegal.com/submit-form/?case_id=45681 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. If you wish to serve as lead plaintiff, you must move the Court no later than December 15, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the complaint, throughout the Class Period, defendants made false and/or misleading statements, as well as failed to disclose material facts, regarding the distinction between the Nanobodies and monoclonal antibodies, including that: (1) SLK and BIMZELX share the same molecular targets (the inflammatory cytokines IL-17A and IL-17F); (2) SLK's distinct Nanobody structure would not confer a superior clinical benefit over the traditional monoclonal structure of BIMZELX; (3) SLK's distinct Nanobody structure supposed tissue penetration would not translate to clinical efficacy; and (4) based on the foregoing, defendants lacked a reasonable basis for their positive statements regarding SLK's purported superiority to monoclonal antibodies. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the MoonLake class action, go to https://rosenlegal.com/submit-form/?case_id=45681 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277082

All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that these responses are expected to deepen over time

Across all dose groups, 95% (19 of 20 patients) of all evaluable VGPR+ patients achieved minimal residual disease negative status

Data featured in an ASH oral presentation; LINKER-MM4 is the first clinical trial to evaluate a BCMAxCD3 bispecific monotherapy in NDMM and is part of a broad clinical development program evaluating Lynozyfic-based regimens in earlier lines of treatment

Regeneron to host virtual ‘Regeneron Roundtable’ investor event to discuss its multiple myeloma development program on Wednesday, December 10 at 8:30 a.m. ET 

TARRYTOWN, N.Y., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced encouraging data from the Phase 1/2 LINKER-MM4 trial evaluating Lynozyfic™ (linvoseltamab) in adults with newly diagnosed multiple myeloma (NDMM) who were transplant eligible or ineligible were shared in an oral presentation at the American Society of Hematology (ASH) Annual Meeting. These data build on results from a broad clinical development program evaluating Lynozyfic in early lines of treatment, including precursor conditions, as monotherapy and in combination with standard-of-care or novel agents.

“The treatment of newly diagnosed multiple myeloma often relies on complicated combinations of quadruplet or triplet regimens, each with its own toxicities, in order to achieve rapid and durable responses, which can be incredibly burdensome for these patients,” said Robert Orlowski, M.D., Ph.D., Deputy Chair, Professor of Medicine, and Director of Translational Myeloma Research in the Departments of Lymphoma/Myeloma and Experimental Therapeutics at The University of Texas MD Anderson Cancer Center and the lead investigator for the LINKER-MM4 trial. “As the first to evaluate a BCMAxCD3 bispecific monotherapy in this setting, LINKER-MM4 seeks to understand whether frontline intervention with a single agent can deliver strong efficacy, enabling the simplification and potentially greater tolerability of these regimens. Lynozyfic monotherapy is already achieving MRD negativity rates comparable to quadruplet regimens but earlier in the treatment course, and these compelling results are expected to deepen with longer follow up. These results underscore Lynozyfic’s potential as a foundational component of frontline treatment regimens for multiple myeloma – or even a monotherapy regimen – for both transplant-eligible and transplant-ineligible patients.”

LINKER-MM4 is an ongoing, open-label Phase 1/2 trial investigating Lynozyfic in adults with NDMM. During a Phase 1A (dose escalation) cohort, patients were treated with a step-up dosing regimen followed by 50 mg, 100 mg or 200 mg doses of Lynozyfic. The lowest (50 mg) and highest (200 mg) tolerated doses were selected for further evaluation in the Phase 1B (dose-expansion) cohort. Among the 45 treated patients in both Phase 1A and 1B, 28 were transplant eligible, and 17 were transplant ineligible.

Across all dose levels (n=45), there was a 1.2 months median time to onset of response (range: 1-4.5 months). All three dose groups (50 mg, 100 mg and 200 mg) showed impressive efficacy, with a VGPR+ (very good partial response or better) of ≥70% with limited follow-up. Evidence shows that these responses are expected to deepen over time. Across all dose groups, 95% (19 of 20 patients) of all minimum residual disease (MRD) evaluable VGPR+ patients achieved MRD negative status at 10-5 sensitivity.

Across all dose levels, the most common treatment-emergent adverse events (TEAEs) were cytokine release syndrome (CRS; all Grade 1: 44%) and neutropenia (any Grade: 38%; Grade 3/4: 33%). Among other adverse events of special interest, one patient in the 50 mg cohort experienced Grade 1 immune effector cell-associated neurotoxicity syndrome (ICANS). Infections occurred in 84% of patients (Grade 1/2: 51%; Grade 3: 33%) with the majority occurring within the first three months of treatment and the rate of infections decreased over time. There were no ≥Grade 4 infections, Grade 5 TEAEs or dose-limiting toxicities. Ten patients elected to undergo an autologous stem cell transplant, all of whom had an acceptable CD34+ stem cell yield post-induction (range: 2.5-11.5 x 106/kg).

A broad clinical development program investigating Lynozyfic in early stages of the disease is underway. This includes the Phase 2 portion of the LINKER-MM4 trial evaluating Lynozyfic at the recommended 200 mg dose, as well as LINKER-MM6 (EMN39), a trial evaluating a combination of daratumumab, lenalidomide and dexamethasone (DRd) followed by Lynozyfic monotherapy compared with continued DRd in transplant-ineligible NDMM.

The use of Lynozyfic described above is investigational, and its safety and efficacy has not been evaluated by any regulatory authority for this indication.

About the ‘Regeneron Roundtable’ Investor Event 
Regeneron will host a virtual investor event to discuss its multiple myeloma program on Wednesday, December 10 at 8:30 a.m. ET. This is the next webcast in a new investor event series called the ‘Regeneron Roundtable,’ intended to highlight programs from the company’s innovative investigational pipeline.

  Links to the webcast and to register via telephone may be accessed from the ‘Investors and Media’ page of Regeneron’s website at 

https://investor.regeneron.com/events-and-presentations. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the company’s website for at least 30 days. 

About Multiple Myeloma
As the second most common blood cancer, there are over 187,000 new cases of MM diagnosed globally every year, with more than 36,000 diagnosed and 12,000 deaths anticipated in the U.S. in 2025. The disease is characterized by the proliferation of cancerous plasma cells (MM cells) that crowd out healthy blood cells in the bone marrow, infiltrate other tissues and cause potentially life-threatening organ injury. Despite treatment advances, MM is not curable, and while current treatments are able to slow progression of the cancer, most patients will ultimately experience cancer progression and require additional therapies.

About Lynozyfic
Lynozyfic was invented using Regeneron’s VelocImmune® technology and is a fully human BCMAxCD3 bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on MM cells with CD3-expressing T cells to facilitate T-cell activation and cancer-cell killing. Lynozyfic is approved to treat certain adults with R/R MM: in the U.S. after four lines of therapy and in the European Union after at least three prior therapies.

In the U.S., the generic name for Lynozyfic in its approved indications is linvoseltamab-gcpt, with gcpt as the suffix designated in accordance with Nonproprietary Naming of Biological Products Guidance for Industry issued by the U.S. FDA. Outside of the U.S., the generic name of Lynozyfic in its approved indications is linvoseltamab.

Lynozyfic is being investigated in a broad clinical development program exploring its use as a monotherapy as well as in combination regimens across different lines of therapy in MM, including earlier lines of treatment, as well as plasma cell precursor disorders. These potential uses are investigational, and their safety and efficacy have not been evaluated by any regulatory authority.  

In addition to LINKER-MM4, ongoing trials include:

LINKER-MM1: Phase 1/2 dose-escalation and dose-expansion trial evaluating the safety, tolerability, dose-limiting toxicities and anti-tumor activity of Lynozyfic monotherapy in R/R MMLINKER-MM2: Phase 1b, open-label trial evaluating Lynozyfic in combination with other cancer treatments in patients with R/R MMLINKER-MM3: Phase 3 confirmatory trial evaluating Lynozyfic monotherapy compared to the combination of elotuzumab, pomalidomide and dexamethasone in R/R MMLINKER-MM5: Phase 3 trial evaluating Lynozyfic monotherapy or in combination with carfilzomib compared to standard of care combination regimens in patients with R/R MMLINKER-MM6 (EMN39): Phase 3 trial, in collaboration with the European Myeloma Network, evaluating daratumumab, lenalidomide and dexamethasone induction followed by Lynozyfic monotherapy compared to continued daratumumab, lenalidomide, and dexamethasone in NDMM who are transplant-ineligiblePhase 1 trial evaluating Lynozyfic in combination with a Regeneron CD38xCD28 costimulatory bispecific in R/R MMLINKER-SMM1: Phase 2 trial evaluating Lynozyfic monotherapy in high-risk smoldering MMLINKER-MGUS1: Phase 2 dose-ranging trial evaluating Lynozyfic monotherapy in high-risk monoclonal gammopathy of unknown significance and non-high-risk SMMLINKER-AL2: Phase 1/2 trial evaluating Lynozyfic monotherapy in R/R systemic light chain amyloidosis 
For more information on Regeneron’s clinical trials in blood cancer, visit the clinical trials website, or contact via [email protected] or 844-734-6643.

IMPORTANT SAFETY INFORMATION FOR U.S. PATIENTS

What is the most important information I should know about LYNOZYFIC?
LYNOZYFIC may cause serious or life-threatening side effects, including Cytokine Release Syndrome (CRS) and infusion-related reactions (IRR), or neurologic problems.

Cytokine Release Syndrome (CRS) and infusion related reactions (IRR). CRS is common during treatment with LYNOZYFIC and can also be serious or life-threatening. Tell your healthcare provider or get medical help right away if you develop any signs or symptoms of CRS or IRR, including:

fever of 100.4ºF (38ºC) or higher fast heartbeat chills or shaking dizziness or light-headedness trouble breathing   Neurologic problems. LYNOZYFIC can cause neurologic problems that can be serious or life-threatening. Tell your healthcare provider or get medical help right away if you develop any signs or symptoms of neurologic problems, including:

headacheagitation, trouble staying awake, confusion or disorientation, seeing or hearing things that are not real (hallucinations)trouble speaking, writing, thinking, remembering things, paying attention, or understanding thingsproblems walking, muscle weakness, shaking (tremors), loss of balance, or muscle spasmsnumbness and tingling (feeling like “pins and needles”)burning, throbbing, or stabbing painchanges in your handwritingseizures Due to the risk of CRS and neurologic problems, you will receive LYNOZYFIC on a “step-up dosing schedule” and should be hospitalized for 24 hours after the first and second “step-up” doses.

During the “step-up dosing schedule”: For your first dose, you will receive a smaller “step-up” dose of LYNOZYFIC on Day 1 of your treatment.For your second dose, you will receive a larger “step-up” dose of LYNOZYFIC, which is usually given on Day 8 of your treatment.For your third dose, you will receive the first treatment dose of LYNOZYFIC, which is usually given on Day 15 of your treatment.Your healthcare provider may repeat one or both of the “step-up” doses depending on side effects or if your treatment is delayed.Before the “step-up” doses and the first two treatment doses of LYNOZYFIC, you will receive medicines to help reduce your risk of CRS and IRR. Your healthcare provider will decide if you need to receive medicine to help reduce your risk of side effects with future doses. LYNOZYFIC is available only through the LYNOZYFIC Risk Evaluation and Mitigation Strategy (REMS) due to the risk of side effects of CRS and neurologic problems. You will receive a Patient Wallet Card from your healthcare provider. Carry the LYNOZYFIC Patient Wallet Card with you at all times and show it to all of your healthcare providers. The LYNOZYFIC Patient Wallet Card lists signs and symptoms of CRS and neurologic problems. Get medical help right away if you develop any of the signs and symptoms listed on the LYNOZYFIC Patient Wallet Card. You may need to be treated in a hospital.

Your healthcare provider will monitor you for signs and symptoms of CRS and neurologic problems during treatment with LYNOZYFIC, as well as other side effects, and may treat you in a hospital if needed. Your healthcare provider may temporarily stop or completely stop your treatment with LYNOZYFIC if you develop CRS, neurologic problems, or any other severe side effects.

If you have any questions about LYNOZYFIC, ask your healthcare provider.

Before receiving LYNOZYFIC, tell your healthcare provider about all of your medical conditions, including if you:

have an infection.are pregnant or plan to become pregnant. LYNOZYFIC may harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with LYNOZYFIC.
Females who are able to become pregnant: Your healthcare provider should do a pregnancy test before you start treatment with LYNOZYFIC.You should use an effective form of birth control (contraception) during treatment with LYNOZYFIC and for 3 months after your last dose of LYNOZYFIC.are breastfeeding or plan to breastfeed. It is not known whether LYNOZYFIC passes into your breast milk. Do not breastfeed during treatment with LYNOZYFIC and for 3 months after your last dose of LYNOZYFIC.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive LYNOZYFIC?

LYNOZYFIC will be given to you by your healthcare provider by infusion through a needle placed in a vein (intravenous infusion).After the “step-up dosing schedule”, the treatment dose of LYNOZYFIC is usually given 1 time each week for 11 doses, and then 1 time every other week for 5 doses. After these doses and based on how your disease responds, your healthcare provider will decide if you are able to receive LYNOZYFIC less often (every 4 weeks) or will continue to have every other week treatment.Your healthcare provider will decide how long you will receive treatment with LYNOZYFIC.If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment. It is important for you to be monitored closely for side effects during treatment with LYNOZYFIC. What should I avoid while receiving LYNOZYFIC?
Do not drive, or operate heavy or potentially dangerous machinery, or do other dangerous activities for 48 hours after completing each of your “step-up” doses or at any time during treatment with LYNOZYFIC if you develop new neurologic symptoms, until the symptoms go away.

What are the possible side effects of LYNOZYFIC?
LYNOZYFIC may cause serious side effects, including:

Infections. LYNOZYFIC can cause bacterial, viral, or fungal infections that are serious, life-threatening, or that may lead to death. Upper respiratory tract infections and pneumonia are common during treatment with LYNOZYFIC. Your healthcare provider will monitor you for signs and symptoms of infection before and during treatment with LYNOZYFIC.Your healthcare provider may prescribe medicines for you to help prevent infections and treat you as needed if you develop an infection during treatment with LYNOZYFIC.Tell your healthcare provider right away if you develop any signs or symptoms of infection during treatment with LYNOZYFIC, including: fever of 100.4 °F (38 °C) or higherchillscoughshortness of breathchest painsore throatpain during urinationfeeling weak or generally unwell Decreased white blood cell counts. Decreased white blood cell counts are common during treatment with LYNOZYFIC and can also be severe. Fever can happen with low white blood cell counts and may be a sign that you have an infection. Your healthcare provider will check your blood cell counts before you start treatment and during treatment with LYNOZYFIC, and will treat you as needed.Liver problems. LYNOZYFIC can cause increased liver enzymes and bilirubin in your blood. These increases can happen with or without you also having CRS. Your healthcare provider will do blood tests to check your liver before starting and during treatment with LYNOZYFIC. Tell your healthcare provider if you develop any of the following signs or symptoms of liver problems: tirednessloss of appetitepain in your right upper stomach-area (abdomen)dark urine yellowing of your skin or the white part of your eyes The most common side effects of LYNOZYFIC include:

muscle and bone pain nausea cough headache diarrheatiredness or weakness shortness of breath The most common severe abnormal blood test results with LYNOZYFIC include: low white blood cell counts and low red blood cell counts.

These are not all of the possible side effects of LYNOZYFIC.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see full Prescribing Information, including Boxed WARNING, and Medication Guide for LYNOZYFIC.

What is LYNOZYFIC?
LYNOZYFIC is a prescription medicine used to treat adults with multiple myeloma who:

have already received at least 4 treatment regimens, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody to treat their multiple myeloma, andtheir cancer has come back or did not respond to prior treatment. It is not known if LYNOZYFIC is safe and effective in children.

About Regeneron in Hematology 
At Regeneron, we’re applying more than three decades of biology expertise with our proprietary VelociSuite® technologies to develop medicines for patients with diverse blood cancers and rare blood disorders.

Our blood cancer research is focused on bispecific antibodies that are being investigated both as monotherapies and in various combinations and emerging therapeutic modalities. Together, they provide us with unique combinatorial flexibility to develop customized and potentially synergistic cancer treatments.

Our research and collaborations to develop potential treatments for rare blood disorders include explorations in antibody medicine, gene editing and gene-knockout technologies, and investigational RNA-approaches focused on depleting abnormal proteins or blocking disease-causing cellular signaling. 

About Regeneron's VelocImmune Technology  
Regeneron's VelocImmune technology utilizes a proprietary genetically engineered mouse platform endowed with a genetically humanized immune system to produce optimized fully human antibodies. When Regeneron's co-Founder, President and Chief Scientific Officer George D. Yancopoulos was a graduate student with his mentor Frederick W. Alt in 1985, they were the first to envision making such a genetically humanized mouse, and Regeneron has spent decades inventing and developing VelocImmune and related VelociSuite technologies. Dr. Yancopoulos and his team have used VelocImmune technology to create a substantial proportion of all original, FDA-approved or authorized fully human monoclonal antibodies. This includes Dupixent® (dupilumab), Libtayo® (cemiplimab-rwlc), Praluent® (alirocumab), Kevzara® (sarilumab), Evkeeza® (evinacumab-dgnb), Inmazeb® (atoltivimab, maftivimab and odesivimab-ebgn) and Veopoz® (pozelimab-bbfg). In addition, REGEN-COV® (casirivimab and imdevimab) had been authorized by the FDA during the COVID-19 pandemic until 2024.

  About Regeneron  
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

Forward-Looking Statements and Use of Digital Media 
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) and research and clinical programs now underway or planned, including without limitation Lynozyfic™ (linvoseltamab-gcpt); the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s Products, such as Lynozyfic as a monotherapy and/or in combination with standard-of-care agents across different lines of therapy in multiple myeloma (“MM”) and plasma cell precursor disorders, including the treatment of adults with newly diagnosed MM as discussed in this press release; uncertainty of the utilization, market acceptance, and commercial success of Regeneron’s Products (such as Lynozyfic) and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing or any potential regulatory approval of Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron’s Products (such as Lynozyfic) and Regeneron’s Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron’s Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes to drug pricing regulations and requirements and Regeneron’s pricing strategy; other changes in laws, regulations, and policies affecting the healthcare industry; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates (including biosimilar versions of Regeneron’s Products); the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics on Regeneron's business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2024 and its Form 10-Q for the quarterly period ended September 30, 2025. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals).

, /PRNewswire/ -- 

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of agilon health, inc. (NYSE: AGL) resulting from allegations that agilon health may have issued materially misleading business information to the investing public.

So What: If you purchased agilon health securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=46039 https://rosenlegal.com/submit-form/?case_id=39889or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

What is this about: On August 4, 2025, agilon health issued a press release entitled "agilon health Reports Second Quarter 2025 Results." Commenting on the results, agilon health's Executive Chair stated that "as we progressed through this transition year, it's become clear that the industry headwinds are more acute than previously expected[.]" Further, the release announced that the company was "suspending its previously issued full-year 2025 financial guidance and related assumptions."

On this news, agilon health's stock fell 51.5% on August 5, 2025.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions.  Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

2 mins mins

Key Points:

Jupiter’s inaccurate risk claims corrected, raising transparency concerns.Jupiter Lend vaults involve rehypothecation, despite initial claims.Kamino raises issues with Jupiter’s risk model clarity.
Jupiter Exchange COO Kash Dhanda acknowledged inaccuracies in the company’s marketing of Jupiter Lend’s vaults, admitting to community concerns about asset rehypothecation, during a video statement on X.

This admission impacts transparency in DeFi protocols, highlighting the controversy over risk models and collateral use, which sparked debates within the Solana DeFi community.

Jupiter Corrects Vault Risk Claims Amid Community Backlash
Jupiter Exchange’s recent clarification regarding Jupiter Lend vaults’ risk model has heightened scrutiny within the crypto community. COO Kash Dhanda admitted past claims of “zero contagion risk” were incorrect. The company now confirms the presence of asset rehypothecation, altering previous narratives about vault isolation. This shift in narrative has prompted Kamino Finance to block migration tools for Jupiter Lend, citing unreliable risk assessments. Concerns over accurate risk communication remain a focal point in evaluating DeFi protocols.

Kamino Finance’s co-founder Marius Ciubotariu publicly criticized Jupiter’s initial risk presentation, arguing that asset rehypothecation disputes the isolated vault narrative. This criticism highlights broader industry tensions over DeFi transparency.

Solana Market Moves Amid DeFi Risk Disclosure
Did you know? The acknowledgment of inaccurate risk claims by Jupiter Exchange echoes a pattern seen in past DeFi communications, where misrepresented risk leads to scrutiny and market distrust.

According to CoinMarketCap, Solana’s current price is $134.90, with a market cap of $75.63 billion. It holds a 2.44% market dominance. Over the past 24 hours, the trading volume reached $3.23 billion, showing a 38.06% increase. Recent price movement includes a 1.44% rise within 24 hours but a decline of 16.24% over 30 days.

Solana(SOL), daily chart, screenshot on CoinMarketCap at 18:01 UTC on December 7, 2025. Source: CoinMarketCap

Coincu research team indicates potential regulatory implications for DeFi protocols in maintaining clear risk models. Enhanced transparency is crucial to ensuring investor trust and avoiding market volatility due to misinformation or insufficiencies in risk communication.

DISCLAIMER: The information on this website is provided as general market commentary and does not constitute investment advice. We encourage you to do your own research before investing.

Rate this post

On December 6, 2025, the co-founder of Kamino, a competing lending platform, publicly challenged Jupiter’s assertions regarding their “isolated vaults” and responded by disabling a migration feature. The dispute highlights increasing tensions within the decentralized finance (DeFi) sector, as platforms vie to assure users of their security and reliability.

Jupiter’s executive team recently admitted that their previous statements about the “zero contagion” nature of their isolated vaults were not entirely accurate. This admission came in the wake of criticism from Kamino and other industry observers, who argued that Jupiter’s marketing created misconceptions about the safety of their product. The term “zero contagion” was intended to suggest that the isolated vaults could safeguard user assets from risks affecting the broader system. However, this characterization was later deemed misleading, as the inherent complexities and interconnectedness of DeFi platforms make absolute isolation challenging to achieve.

Kamino’s co-founder expressed frustration with Jupiter’s communication strategy, emphasizing that by overstating the security of their vaults, Jupiter not only misled users but also potentially undermined trust in decentralized finance innovations. This incident underscores the growing need for transparency and accountability in the rapidly evolving crypto ecosystem, where investors often rely heavily on technical claims to guide their decisions.

The crypto market’s expansion has been marked by both tremendous opportunities and significant risks. As of 2023, DeFi had grown to manage billions in assets, with the rise of novel financial products pushing the boundaries of traditional finance. However, this growth has also attracted scrutiny from regulators and industry insiders concerned about systemic risks and the potential for large-scale financial disruption.

The situation with Jupiter reflects broader challenges facing DeFi projects. The complexity and novelty of these financial products inherently carry risks that can be difficult for average investors to fully understand. The promise of high returns often overshadows the underlying vulnerabilities, leading to a delicate balance between innovation and security.

In response to the backlash, Jupiter has committed to revisiting their promotional materials and refining their messaging to more accurately reflect the features and limitations of their isolated vaults. This includes a pledge to work closely with third-party auditors and enhance security protocols. Their willingness to acknowledge and address these issues is a positive step towards regaining user trust.

Nonetheless, the incident raises questions about the oversight and regulation of DeFi platforms. Unlike traditional financial institutions, which are subject to stringent regulatory scrutiny, many DeFi operators operate in a largely unregulated environment. This lack of oversight can lead to scenarios where platforms make bold claims without sufficient evidence or accountability.

The rival platform, Kamino, has capitalized on the situation by emphasizing its own security protocols and transparency in its operations. By halting the migration tool, Kamino signaled its disapproval of Jupiter’s practices, aiming to position itself as a more trustworthy alternative in the competitive DeFi landscape. Kamino’s actions highlight the importance of peer accountability in the absence of external regulatory pressures.

In the broader context of financial markets, the DeFi sector’s rapid growth resembles the early days of the internet, where innovation outpaced regulation. Just as the dot-com bubble burst was followed by a wave of regulatory interventions and more sustainable growth, it is possible that DeFi will undergo similar transformations. For the sector to mature, industry leaders need to collaborate with regulators to establish standards that protect investors while fostering innovation.

A potential risk facing Jupiter and similar platforms is the erosion of user confidence. In decentralized systems, trust is a critical component of success, and losing it can lead to a rapid outflow of capital. If users perceive a platform as unreliable, they may move their assets to competitors, which could destabilize the platform’s financial structure. Therefore, maintaining a reputation for integrity and transparency is essential for survival in the competitive DeFi market.

Looking forward, the crypto community must balance the lure of cutting-edge financial technology with a commitment to accuracy and responsibility. As platforms like Jupiter navigate these challenges, they can draw lessons from traditional financial sectors, where transparency and customer protection are paramount.

Ultimately, the path forward for Jupiter and its peers hinges on their ability to innovate responsibly. By embracing transparency and engaging in honest dialogue with users and competitors, they can help pave the way for a more secure and reliable DeFi ecosystem. This approach will not only benefit individual platforms but also contribute to the overall credibility and sustainability of decentralized finance as a whole.

Post Views: 14

Russian President Vladimir Putin asserted only a year ago that no power can ban Bitcoin (CRYPTO: BTC) regardless of what happens to the dollar. While many saw it as a message to the West on international sanctions, the country has taken targeted steps to open its economy to the world’s largest cryptocurrency.

Bitcoin Will Continue To Grow, Said PutinDuring an investment conference in Moscow on Dec. 4, 2024, Putin argued that the influence of the dollar on the global economy was waning, paving the way for the growth of other instruments.

“For instance – Bitcoin. Who can prohibit its use? No one,” Putin said. “Or the use of other electronic ways of settlement. No one can ban the use of them.”

Putin added that the new instruments would “continue developing” regardless of what happens to the dollar.

Crypto To Bypass Russia’s Trade DisruptionsShortly after these comments, Russia’s Finance Minister Anton Siluanov revealed that Russian companies have started using Bitcoin and other cryptocurrencies for cross-border transactions, described as a response to trade disruptions from sanctions imposed after the Ukraine war.

The minister said that it was possible to use the Bitcoin mined in Russia in foreign trade.

It’s worth noting that Putin greenlighted Bitcoin mining in the country earlier that year. He previously rejected the central bank's proposal to ban cryptocurrencies in 2022, arguing that the country possesses "competitive advantages" in the field of mining.

See Also: Ex-SEC Chair Gary Gensler Warns Crypto Remains ‘Speculative, Volatile’

Bank Of Russia’s Plan To Broaden Crypto AccessIn accordance with Putin’s directives, the central bank proposed in March of this year to allow a limited number of “highly qualified” Russian investors to purchase and sell cryptocurrencies under a new three-year experimental legal regime.

The bank maintained that it still doesn’t see cryptocurrency as a means of payment and proposed a ban on all cryptocurrency transactions between Russian residents outside the experimental regime.

However, recent developments suggest attempts to expand cryptocurrency access for Russians. Bank of Russia First Deputy Governor Vladimir Chistyukhin said that rules should be eased beyond the “extremely narrow” category of qualified investors, given the sanctions in place, according to a Cryptopolitan report.

How Big Is Russia’s Bitcoin Mining Industry?Maxim Oreshkin, the Deputy Chief of Staff of the Presidential Executive Office, said earlier this week that cryptocurrency mining generates “enormous sums” and must be factored into Russia’s balance of payments, according to a report by Vedomosti, the country’s leading business newspaper.

There is no publicly available official figure for how much Bitcoin the Russian government holds. Although, calculations from Russia’s National Cryptomining Association showed that 54,000 BTC were mined in 2023 alone.

Price Action: At the time of writing, BTC was exchanging hands at $$91,968.59, up 1.35% in the last 24 hours, according to data from Benzinga Pro.

Photo Courtesy: miss.cabul on Shutterstock.com

Read Next: 

If You’re Expecting A Bitcoin Bear Market In 2026, You Have It Wrong, Grayscale Says
Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

This week, high-caps fell below key levels. Here's a look at how some of your favorite coins fared.

As of December 7, 2025, Ethereum has incinerated over six million ETH through transaction fees since the London upgrade on August 5, 2021, equivalent to more than $18 billion at current exchange rates. Despite this massive burn, Ethereum’s overall supply continues to grow, presenting a paradox in the realm of cryptocurrency economics.

The London hard fork introduced a significant change to Ethereum’s monetary policy through the implementation of EIP-1559, a protocol aiming to stabilize transaction fees and enhance user experience. By converting a portion of transaction fees into a base fee that gets ‘burned’ or removed from circulation, it was anticipated that Ethereum’s supply might decrease, driving up its price due to scarcity principles. However, the Ethereum network’s supply has paradoxically increased, driven by factors that extend beyond the mere destruction of ETH.

Ethereum’s capacity to burn over six million ETH has been driven by its role as a leading decentralized finance (DeFi) platform. As DeFi applications continue to expand, the demand for Ethereum’s network has surged. This demand fuels transactions, consequently increasing the amount of ETH burned. Yet, as the network burns ETH, it also incentivizes miners through ‘block rewards,’ a process where new coins are created and distributed to miners for validating transactions. This continuous minting of new ETH has contributed to the overall increase in supply, counterbalancing the effects of burning.

In the broader context of cryptocurrency ecosystems, Ethereum’s burning mechanism aims to address some of the inflationary pressures that affect many digital currencies. Unlike Bitcoin, which has a capped supply of 21 million coins, Ethereum does not have a maximum supply limit. This lack of a cap means that without mechanisms like burning, Ethereum’s supply could theoretically expand indefinitely, potentially diminishing its value over time. By strategically burning a portion of fees, Ethereum attempts to navigate the delicate balance between maintaining a robust network and sustaining value for its holders.

The Ethereum network operates as the backbone of numerous blockchain applications, including smart contracts and non-fungible tokens (NFTs). The intrinsic value and utility of these applications drive transaction volumes, which are critical to ETH’s burning mechanism. Since the London upgrade, the network has seen a significant increase in adoption, which has fueled both growth and the complexity of its economic model.

However, Ethereum’s supply dynamics are not without their risks and challenges. One potential risk is the network’s transition to Ethereum 2.0, a proof-of-stake model designed to improve security and scalability. This transition could significantly alter the supply-demand landscape. As Ethereum shifts from proof-of-work to proof-of-stake, validators will replace miners, earning rewards for their commitment rather than computational power. The change could influence how ETH is issued and burned, impacting overall supply and possibly altering market perceptions.

Moreover, the cryptocurrency market is subject to regulatory scrutiny and evolving policies, which can affect Ethereum’s economic model. Regulatory changes in major markets could influence how cryptocurrencies like Ethereum are traded, held, and used, potentially impacting demand and supply. The ongoing debate around digital currency regulation underscores the importance of proactive governance in the crypto space.

Ethereum’s journey since the London hard fork illustrates the intricate balance of supply and demand within a rapidly evolving financial ecosystem. Despite burning significant amounts of ETH, the network’s growth and the continuous creation of new ETH through mining have maintained a steady supply increase. This scenario highlights the complexity of managing a decentralized currency system where various economic forces interact.

The digital currency market remains highly volatile, and Ethereum’s supply and demand dynamics are a reflection of this volatility. While the burning of ETH aims to introduce deflationary pressure, the simultaneous creation of new ETH through rewards presents a balancing act. Investors and participants in the Ethereum ecosystem must navigate this complexity, understanding the broader market conditions and economic principles at play.

In summary, the burning of over six million ETH underscores both the potential and the challenges of Ethereum’s economic model. By implementing mechanisms like EIP-1559, Ethereum attempts to balance network growth with value preservation. Yet, the supply increase suggests that burning alone is not a panacea for inflationary pressures. As Ethereum continues to evolve, its economic dynamics will be closely watched by investors, developers, and regulators alike, as they look to understand and harness the potential of this leading cryptocurrency.

Post Views: 12

3 mins mins

Key Points:

Bitget launches POWERUSDT perpetual contract on December 6, 2025Leverage options range from 1 to 20, with trading bots supportedEvent marks expansion in Bitget’s U-Index perpetual offerings
On December 6, 2025, Bitget launched the POWERUSDT perpetual contract, introducing leverage options ranging from 1 to 20, and activated trading bots, according to their official announcement.

This move underscores Bitget’s ongoing expansion of U-Index-based derivatives, potentially influencing market dynamics for synthetic assets while highlighting advanced trading tools available on the platform.

Bitget Expands U-Index Offerings with POWERUSDT Launch
Bitget announced the POWERUSDT perpetual contract’s initiation, offering leverage from 1 to 20 times. Gracy Chen, CEO of Bitget, highlighted this product as part of Bitget’s broader strategy to expand its U-Index-based offerings. Both the perpetual contract and its corresponding trading bot became active on December 6, 2025, further enriching Bitget’s derivative market tools.

Incorporating this contract deepens Bitget’s commitment to providing diversified trading instruments. It broadens traders’ and investors’ capabilities for exposure to synthetic derivatives, structured to mirror real-world asset indices. With varying leverage options, traders can adjust their risk profiles to suit market conditions. This addition also introduces potential for fluctuating financial exposures via automated trading bots for this contract’s management.

Bitget has launched POWERUSDT for futures trading with a maximum leverage of 20, along with support for futures trading bots, on December 6, 2025 (UTC+8).Market reactions from leading experts in the cryptocurrency ecosystem appeared muted, with no significant public comments from notable figures in crypto communities. The general feedback from industry circles focused on Bitget’s strategic continuity in expanding derivative offerings with standardized features.

Price Impact and Future Market Potential
Did you know? Power Protocol’s launch of POWERUSDT follows a consistent precedent set by Bitget, notably its BSUUSDT launch earlier on December 4, 2025, highlighting a methodical pattern in expanding U-Index offerings.

Power Protocol’s token, POWER, currently trades at $0.20, with a market cap of approximately $42.67 million. Over the past 24 hours, its trading volume reached around $65.97 million, experiencing an 11.75% decline. Remarkably, the token saw a 150.95% increase over the past month, indicating heightened market interest. All figures are sourced from CoinMarketCap.

Power Protocol(POWER), daily chart, screenshot on CoinMarketCap at 18:58 UTC on December 7, 2025. Source: CoinMarketCap

Insights from the Coincu research team suggest this ongoing expansion by Bitget into U-Index offerings could shape future trends in synthetic asset derivatives. Past launches hint at regulatory stability, assuming no new legal challenges arise, thus fostering continued innovative financial product developments within Bitget’s ecosystem.

DISCLAIMER: The information on this website is provided as general market commentary and does not constitute investment advice. We encourage you to do your own research before investing.

Rate this post

Bitcoin’s Sunday price action turned chaotic after a wave of whale-driven sell orders triggered a rapid $2,000 drop, mass liquidations, and an equally aggressive rebound.

The moves wiped out both long and short traders within hours, raising fresh concerns about low-liquidity manipulation and order book fragility at a time when Bitcoin continues hovering above $91,000.

Sponsored

Sponsored

$1.39 Billion in Bitcoin Dumped Within One HourSeveral analysts reported a what appeared to be coordinated sell-offs, where more than 15,565 BTC, worth roughly $1.39 billion, hit the market in a single hour.

“Here is why the market just nuked: whale dumped 4,551 BTC, Coinbase dumped 2,613 BTC, Wintermute dumped 2,581 BTC, Binance dumped 2,044 BTC, BitMEX dumped 1,932 BTC, Fidelity dumped 1,844 BTC. A total of 15,565 BTC worth $1.39 billion was dumped in one hour! This was a full-scale coordinated sell-off,” wrote analyst Wimar in a post.

The sudden surge in supply hitting the market simultaneously accelerated Bitcoin’s decline from $89,700 to $87,700, setting the stage for a cascade of liquidations.

$171 Million in Liquidations as Longs and Shorts Get WipedThe sharp initial drop wiped out $171 million worth of BTC longs, caught off guard as the Bitcoin price fell $2,000 in minutes before rebounding with equal force. As of this writing, the Bitcoin price is $91,494.

Bitcoin (BTC) Price Performance. Source: TradingViewAlong with this quick recovery, almost $14 million in short positions were liquidated in the past hour and over $91 million in the past four hours.

Sponsored

Sponsored

“This is another example of manipulation on the low-liquidity weekend to wipe out both leveraged longs and shorts,” Bull Theory said.

Data from Coinglass confirms the scale of the damage. Over the past 24 hours, 121,628 traders were liquidated, resulting in total liquidations of $346.67 million.

Crypto Liquidations. Source: CoinglassTraders Call It “Engineered Liquidity Collection”Market commentators say this wasn’t normal volatility, with Marto arguing that the sequence was not accidental.

Sponsored

Sponsored

“People keep calling this volatility. It’s not. It’s engineered liquidity collection. When the order book is weak, whales swing the price like a door hinge and cash in on both sides,” he wrote.

Others pointed to the speed of the recovery, with Lenny, a trader known for tracking liquidity flows, remarking about the whipsaw.

“Honestly, that BTC dip to 89k got absorbed fast. That’s not noise,” Lenny chimed.

The quick absorption suggests strong spot demand remains intact even as aggressive leverage flushes continue at weekend lows.

Sponsored

Sponsored

Can Bitcoin Maintain $90,000?The Bitcoin price is recovering its weekend losses but still showing signs of heavy intraday stress. The dual liquidations demonstrate how thin order books on weekends continue to be a target for large players capable of moving billions of dollars in minutes.

Spot demand may stabilize price action into the upcoming week, especially as liquidity normalizes and derivatives markets reset.

With over $300 million in liquidations behind it, Bitcoin enters the next trading sessions with cleared leverage, but also heightened sensitivity to further whale-driven moves.

Meanwhile, data shows that $1 billion in short positions are at risk of liquidation if the Bitcoin price pumps to $93,000.

Notably, the $93,000 threshold stands barely 2% above current levels.

BPCE launches in-app trading for BTC, ETH, SOL, and USDC, marking a major shift as European banks race to meet rising retail crypto demand.

Izabela Anna2 min read

7 December 2025, 07:31 PM

France’s banking landscape is shifting as BPCE begins offering direct crypto purchases to a segment of its retail customers. The group now enables access to Bitcoin, Ether, Solana, and USDC through its regional networks. The launch signals a major step by a traditional financial institution entering an increasingly competitive digital asset sector. 

Early Rollout Targets Two Million CustomersBPCE introduced the service within four regional entities, including Banque Populaire Île-de-France and Caisse d’Épargne Provence-Alpes-Côte d’Azur. These entities represent around two million customers. The group plans to introduce the service across its remaining networks during 2026. However, executives want to monitor performance before accelerating expansion.

Customers can buy or sell supported assets through the Caisse d’Épargne and Banque Populaire apps. Each user creates a dedicated digital asset account that carries a monthly fee of €2.99. Moreover, each transaction includes a 1.5% commission with a €1 minimum. Hexarq, BPCE’s crypto subsidiary, manages all related accounts.

European Banks Intensify Their Crypto PushEuropean banks are expanding digital asset services as more consumers seek regulated access. Fintech competition increased pressure on traditional banks. Apps like Revolut, Deblock, Bitstack, and Trade Republic attracted millions of crypto users across Europe. Consequently, major banks now view digital assets as an important retention tool.

Several institutions already moved ahead. BBVA allows Spanish customers to buy, sell, and hold Bitcoin and Ether through its app. Additionally, Santander’s digital unit Openbank added Bitcoin, Ether, Litecoin, Polygon, and Cardano with integrated trading and custody. These developments show rising confidence among banks exploring broader crypto strategies for retail clients.

BPCE Aims to Strengthen Its Retail PositionBPCE sees digital assets as a way to strengthen customer loyalty during rapid fintech disruption. Moreover, the bank expects growing interest as users seek simple crypto access through familiar platforms. 

The phased rollout helps BPCE collect data and refine the service. This approach also prepares the bank for larger demand once digital asset regulations adjust across Europe.

Significantly, the move aligns with a wider trend in European banking that supports regulated access instead of external platforms. BPCE plans to position itself as a reliable and convenient gateway for everyday investors.

ENRICH your inbox with our best storiesDon’t miss out and join our newsletter to get the latest,
well-curated news from the crypto world!

Izabela Anna

Izabela Anna is a knowledgeable freelance journalist, who boasts over five years of experience covering the cryptocurrency market. Her tenure has seen her navigate through the ebbs and flows of multiple market cycles, giving her a deep understanding within. Her journalistic focus lies in dissecting price action dynamics, scrutinizing the on-chain landscape, and providing insights from a technical perspective, making her a trusted voice in the realm of cryptocurrency reporting.

Read more about

Latest Solana (SOL) News Today

After spending the morning flirting with the dungeon below $88,000, BTC clawed its way upward and blasted to an intraday high of $91,767. Bitcoin's latest rebound didn't just flip the script on weekend traders — it triggered a full-blown liquidation bonfire across the crypto market as deep-pocketed buyers muscled shorts into oblivion.

TLDR:

Binance futures open interest prints turn negative, signaling traders are reducing leveraged exposure during Bitcoin’s pullback.

Funding rates drop sharply, showing long-side aggression easing and derivatives pressure cooling across recent sessions.

Binance Leverage Pulse at 0.198 sits below its 20-day average, indicating stable leverage relative to stablecoin reserves.

A collective reset across OI, funding, and leverage supports Bitcoin’s steady trade within the crucial 86–88K support range.

Bitcoin Stabilizes at 86–88K as the market enters a quieter derivatives phase on Binance, where leverage metrics show a steady reset rather than stress.

The move from 89.6K toward the lower 89K region unfolds during a moment of reduced speculative positioning, giving Bitcoin room to trade within this key support zone. Conditions remain orderly, with traders stepping back from aggressive leverage as the market cools.

This reset is visible across multiple metrics that track behavior on Binance’s futures market. 

Open interest and funding readings both point to a broad step-down in leveraged exposure. The environment is not showing signs of panic or disorder; instead, it reflects controlled positioning as Bitcoin holds its range.

Open Interest and Funding Ease as Market Cools
Open interest readings on the 12-hour window turned negative at –0.18%, –0.24%, and –0.53%. 

These values show traders reducing exposure rather than increasing speculative bets. Such behavior often appears during resets that follow extended upward moves, allowing the market structure to stay stable during pullbacks.

Open Interest and Funding Ease as Market CoolsSource: Cryptoquant
Funding data also moved sharply lower with readings of –69%, –62%, –49%, and –40%. These drops suggest a slowdown in long-leaning positioning across Binance Futures. 

With fewer traders attempting to push the price through leverage, Bitcoin’s move into the 86–88K zone develops in a relatively calm setting.

Crazzyblockk shared these metrics to show that the futures market is cooling at the right time. The absence of rising leverage during this dip supports a more balanced structure. Traders on Binance appear to be waiting rather than preparing for a deeper slide.

Leverage Pulse Shows Controlled Conditions
The Binance Leverage Pulse (ST_ELR) provides another reference point. 

The latest reading at 0.198 sits below the 20-day average of about 0.205. The negative z-score indicates that leverage relative to stablecoin reserves remains contained during this stage.

Source: Cryptoquant
A controlled leverage pulse reduces the risk of forced liquidations, which often accelerate volatility during pullbacks. 

With this metric cooling in tandem with open interest and funding, Bitcoin’s position near the 86–88K range gains a steadier foundation. The market appears to be resetting rather than showing stress signals.

According to Crazzyblockk, Binance’s influence on global Bitcoin sentiment remains central. 

When leverage activity cools across all core indicators, conditions often support a slow rebuilding phase. As long as Bitcoin maintains the 86–88K support zone, this quieter derivatives backdrop may provide space for a more measured recovery.

Privacy-focused Ethereum Layer 2 developer Aztec Network closed its public AZTEC token sale Saturday, collecting 19,476 ETH from more than 16,700 participants in what the project claims represents a shift away from insider-dominated token launches.

The sale, which ran from December 2-6 using a novel Continuous Clearing Auction mechanism built with Uniswap Labs, raised approximately $61.3 million at current ether prices. Aztec said half of the capital came from its existing community, such as testnet operators, early users of its now-shuttered Aztec Connect product, and other ecosystem participants, rather than large institutional allocations.

Aztec's token distribution eschewed the airdrop model that has become standard for Layer 2 launches in favor of what it described as a "fair-access" auction. The CCA mechanism started at a floor price corresponding to a $350 million fully diluted valuation, which Aztec said represented a 75% discount to the implied valuation from its equity financing rounds. Per-user caps of 240 ETH were instituted to limit whale concentration.

Uniswap founder Hayden Adams praised the sale in a post on X. "No sniping, bundling, timing games," Adams wrote. "Just slow, fair price discovery ending at 59% above the floor — with literally days to bid earlier and get a better average price."

A Uniswap v4 liquidity pool containing 273 million AZTEC tokens (roughly 2.6% of total supply) will also go live following the token generation event to bootstrap secondary market trading.

AZTEC tokens purchased through the sale will remain non-transferable until at least February 11, 2026. Token holders can then initiate a governance vote to unlock transferability. If no vote passes, tokens will unlock linearly through November 2026. Validators wishing to stake must commit 200,000 AZTEC tokens.

The a16z-backed project had raised $100 million in Series B funding in December 2022, with additional backing from Paradigm and Ethereum co-founder Vitalik Buterin. The company has raised over $119 million in total funding, per The Block Pro's Funding Dashboard. 

Aztec launched its privacy-focused Ethereum Layer 2 network, Ignition Chain, in mid-November. Aztec called Ignition the "first fully decentralized L2 on Ethereum," which will power the firm's vision of a "private world computer."

165 nodes are currently powering the network, according to the project's dashboard. The chain is currently producing blocks but does not yet process user transactions, a deliberate staging approach the team says will allow real economic stress-testing before full functionality launches in early 2026. Nearly 556 million AZTEC tokens have been staked. 

Disclaimer: The Block is an independent media outlet that delivers news, research, and data. As of November 2023, Foresight Ventures is a majority investor of The Block. Foresight Ventures invests in other companies in the crypto space. Crypto exchange Bitget is an anchor LP for Foresight Ventures. The Block continues to operate independently to deliver objective, impactful, and timely information about the crypto industry. Here are our current financial disclosures.

© 2025 The Block. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

With Bitcoin now in its fourth quadrennial halving, other decentralized projects have adopted similar supply-cut cycles — and Bittensor is approaching its first since launching in 2021.

Bittensor, a decentralized, open-source machine-learning network built around specialized “subnets” that incentivize marketplaces for AI services, is expected to undergo its inaugural halving on or around Dec. 14. At that point, issuance of its native token, TAO (TAO), will drop to 3,600 per day from the current 7,200.

Grayscale Research analyst William Ogden Moore called the event a “key milestone in the network’s maturation as it progresses toward its 21 million token supply cap,” matching Bitcoin’s (BTC) fixed limit.

TAO follows a supply schedule similar to Bitcoin’s. Source: Grayscale ResearchDigital-asset investors and network participants often view a hard-capped supply as a potential value catalyst: if adoption grows and token demand rises, a finite issuance model can be more appealing than pre-mined tokens or fiat currencies with effectively unlimited supply.

Cointelegraph reported on Bittensor in May during a conversation with DNA Fund’s Chris Miglino, whose AI compute fund is heavily involved in the Bittensor ecosystem.

“The biggest thing that we’re working on in the whole ecosystem is our AI compute fund, where we’ve been entrenched into the TAO ecosystem,” Miglino said.

A dive into Bittensor subnetsGrayscale describes Bittensor’s subnets as a kind of “Y Combinator for decentralized AI networks,” since each operates like a startup building a specialized product or service.

CoinGecko currently lists over 100 Bittensor subnets, with a combined market cap exceeding $850 million. Taostats, which tracks the ecosystem more comprehensively, shows 129 subnets with a total market cap closer to $3 billion.

The growth of Bittensor subnets. Source: CoinGeckoIn either case, subnet valuations have grown significantly since launch, according to Grayscale Research. The largest include Chutes, which provides serverless compute for AI models, and Ridges, a subnet focused on crowdsourcing the development of AI agents.

The expansion underscores growing demand for decentralized AI infrastructure as developers race to build and scale new AI products and applications.

As Miglino told Cointelegraph, decentralized AI may prove to be blockchain’s most significant use case since Bitcoin, driven largely by that demand.

Bittensor subnets are also drawing venture capital. Inference Labs recently closed a $6.3 million round to support Subnet 2, a Bittensor marketplace for inference verification.

Meanwhile, xTao, an infrastructure developer building tools and services for the Bittensor ecosystem, began trading on the TSX Venture Exchange in July as a newly public company.

Information in Investor’s Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, or suitability, including with respect to information that appears in closed captioning. Historical investment performances are no indication or guarantee of future success or performance. Authors/presenters may own the stocks they discuss. We make no representations or warranties regarding the advisability of investing in any particular securities or utilizing any specific investment strategies. Information is subject to change without notice. For information on use of our services, please see our Terms of Use.

*Real-time prices by Nasdaq Last Sale. Real-time quote and/or trade prices are not sourced from all markets. Ownership data provided by LSEG and Estimate data provided by FactSet.

IBD, IBD Digital, IBD Live, IBD Weekly, Investor's Business Daily, Leaderboard, MarketDiem, MarketSurge and other marks are trademarks owned by Investor's Business Daily, LLC.

©2025 Investor’s Business Daily, LLC. All Rights Reserved.

One specialty manufacturer is drawing fresh hedge-fund attention—and it isn’t because of consumer gadgets.

On November 14, New York-based Harvey Partners disclosed a new position in Knowles Corporation (KN 0.17%), adding 622,500 shares valued at approximately $14.5 million during the third quarter.

What HappenedAccording to a filing with the Securities and Exchange Commission dated November 14, Harvey Partners established a new position in Knowles Corporation (KN 0.17%). The firm reported a holding of 622,500 shares, amounting to a market value of approximately $14.5 million as of September 30. The position accounts for 1.3% of the fund’s reportable U.S. equity assets.

What Else to KnowTop holdings after the filing: 

NYSE: NPO: $56.3 million (5.1% of AUM)NYSE: BWXT: $53.4 million (4.9% of AUM)NYSE: AZZ: $53 million (4.8% of AUM)NASDAQ: GLDD: $44.4 million (4% of AUM)NASDAQ: ADEA: $43.9 million (4% of AUM)As of Friday, shares of Knowles Corporation were priced at $23.37, up 20% over the past year and well outperforming the S&P 500, which is up 13% in the same period.

Company OverviewMetricValuePrice (as of market close Friday)$23.37Market Capitalization$2 billionRevenue (TTM)$573.5 millionNet Income (TTM)$35.8 millionCompany SnapshotKnowles Corporation offers micro-acoustic microphones, balanced armature speakers, audio processors, high-performance capacitors, and RF solutions across consumer electronics, medtech, defense, electric vehicle, industrial, and communications sectors.The company generates revenue by designing, manufacturing, and selling audio and precision device components to original equipment manufacturers, contract manufacturers, and distributors worldwide.Primary customers include global OEMs in mobile, hearing health, IoT, computing, medical, satellite communications, and industrial markets.Knowles Corporation is a leading provider of advanced micro-acoustic, audio, and precision device solutions with a global footprint and a diversified customer base. The company leverages decades of expertise to serve high-growth markets such as mobile communications, hearing health, and industrial electronics.

Foolish TakeA new position in a volatile name like Knowles matters because it signals where managers see durable demand. In other words, Harvey Partners’ move might suggest confidence that Knowles’ exposure to diversified end-markets—from hearing health to defense and industrial electronics—can support steadier earnings even when consumer hardware cycles soften.

In the third quarter, Harvey Partners initiated a $14.5 million position, making Knowles a modest but intentional addition at 1.3% of reportable assets. And although shares have traded choppily in recent years, Knowles has outperformed the broader market over the past 12 months, rising 20% versus the S&P 500’s 13% gain.

Recent earnings help explain the interest. Third-quarter revenue grew 7% year over year to $152.9 million, while gross margin expanded to 45.7%, and non-GAAP EPS came in at $0.33—above the midpoint of guidance. Management highlighted strong design activity, a healthy backlog, and reiterated expectations for 6% organic revenue growth this year, with fourth-quarter revenue projected to rise another 9% year over year. The company also generated $29 million in operating cash and repurchased $20 million of stock, underscoring improving fundamentals that long-term investors may view as a stabilizing force despite ongoing share volatility.

Glossary13F reportable assets: Assets that institutional investment managers must disclose quarterly to the SEC, showing their U.S. equity holdings.
Assets under management (AUM): The total market value of investments managed on behalf of clients by a fund or firm.
Alpha: A measure of an investment's performance relative to a benchmark, showing value added or subtracted by active management.
Original equipment manufacturer (OEM): A company that produces parts or equipment used in another company's end products.
Micro-acoustic: Technology involving very small audio components, such as miniature microphones and speakers, for electronic devices.
Balanced armature speakers: Small, precise speakers commonly used in hearing aids and in-ear monitors for accurate sound reproduction.
RF solutions: Products or technologies related to radio frequency, used for wireless communication in electronic devices.
Contract manufacturer: A company hired to produce goods on behalf of another company, often at scale and to specific requirements.
TTM: The 12-month period ending with the most recent quarterly report.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Azz and BWX Technologies. The Motley Fool has a disclosure policy.

With this ETF, investors don't have to sacrifice growth to access reliable, growing dividends.

Investors shopping for top exchange-traded funds (ETFs) can't be blamed if they're focusing on funds holding equities associated with artificial intelligence (AI) and technology. After all, those have been market-leading segments for an extended period.

Still, investors shouldn't get sidetracked. In the quest to identify some of the top ETFs to buy today, the First Trust Rising Dividend Achievers ETF (RDVY +0.16%) merits consideration. This ETF, which turns 12 years old next month, could be a potent addition to a wide variety of portfolios, but before diving in, investors should examine the fund's plumbing.

This tech-heavy dividend fund is one of the top ETFs to consider today. Image source: Getty Images.

This isn't your grandfather's dividend ETF
Home to $18.21 billion in assets under management (AUM) as of Dec. 1, First Trust Rising Dividend Achievers ETF is among the top 10 in terms of size in the dividend ETF category. More important is this ETF's long-running track record of outperforming peers, often by sizable margins.

RDVY Total Return Level data by YCharts

Knowing how First Trust Rising Dividend Achievers ETF generated that stellar run is important because while past performance isn't a guarantee of future returns, a fund's methodology can give investors a sense of what to expect. In the case of this dividend ETF, it focuses on four primary pillars.

First, member firms must have paid a dividend over the trailing 12 months that is "greater than the dividend paid in the trailing twelve-month period three and five years prior." Second, companies eligible for inclusion must have positive earnings over the past year, and those profits must exceed those notched in the prior three fiscal years.

Other mandates include prospective holdings must have cash-to-debt ratios of at least 50% and they can't have trailing 12-month payout ratios in excess of 65%. For some dividend-paying companies, those are high hurdles to clear, but adhering to those guidelines helps this ETF deliver a quality portfolio while steering investors away from yield traps.

The end product is something many investors may view as enticing, as this ETF allocates almost 27% of its roster to tech stocks. It's not common for dividend ETFs to feature Alphabet and Nvidia among their top six holdings, but this ETF breaks from the pack and it's worked out well for investors, helping make this fund one worth looking into.

Todd Shriber has positions in Alphabet. The Motley Fool has positions in and recommends Alphabet, Nvidia, and Vanguard Dividend Appreciation ETF. The Motley Fool has a disclosure policy.

, /PRNewswire/ -- Prologis, Inc. (NYSE: PLD) announced today that Prologis, L.P. will redeem all of its outstanding 3.00% Notes due June 2, 2026 (CUSIP Number 74340XBB6, ISIN XS1072516690 and Common Code 107251669, the "bonds"), following which the bonds will be delisted from the New York Stock Exchange. The redemption price is estimated to be at a price equal to 102.1% of the principal amount of the bonds outstanding, which includes interest accrued to the redemption date for an aggregate payment of approximately €1,021 per €1,000 in principal amount issued and outstanding as of the redemption date (estimated using a current German government bond rate). Interest on the principal amount shall cease to accrue on and after the redemption date, which is January 9, 2026.

ABOUT PROLOGIS
The world runs on logistics. At Prologis, we don't just lead the industry, we define it. We create the intelligent infrastructure that powers global commerce, seamlessly connecting the digital and physical worlds. From agile supply chains to clean energy solutions, our ecosystems help your business move faster, operate smarter and grow sustainably. With unmatched scale, innovation and expertise, Prologis is a category of one–not just shaping the future of logistics but building what comes next. Learn more at Prologis.com.

FORWARD-LOOKING STATEMENTS
The statements in this document that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based on current expectations, estimates and projections about the industry and markets in which we operate as well as management's beliefs and assumptions. Such statements involve uncertainties that could significantly impact our financial results. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "aims," and "estimates" including variations of such words and similar expressions are intended to identify such forward-looking statements, which generally are not historical in nature. All statements that address performance, events or developments that we expect or anticipate will occur in the future—including statements relating to the expected redemption price and the delisting of the bonds—are forward-looking statements. These statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions that are difficult to predict. Although we believe the expectations reflected in any forward-looking statements are based on reasonable assumptions, we can give no assurance that our expectations will be attained and, therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements. Some of the factors that may affect outcomes and results include, but are not limited to: (i) international, national, regional and local economic and political climates and conditions; (ii) changes in global financial markets, interest rates and foreign currency exchange rates; (iii) increased or unanticipated competition for our properties; (iv) risks associated with acquisitions, dispositions and development of properties, including the integration of the operations of significant real estate portfolios; (v) maintenance of Real Estate Investment Trust status, tax structuring and changes in income tax laws and rates; (vi) availability of financing and capital, the levels of debt that we maintain and our credit ratings; (vii) risks related to our investments in our co-investment ventures, including our ability to establish new co-investment ventures; (viii) risks of doing business internationally, including currency risks; (ix) environmental uncertainties, including risks of natural disasters; (x) risks related to global pandemics; and (xi) those additional factors discussed in reports filed with the Securities and Exchange Commission by us under the heading "Risk Factors." We undertake no duty to update any forward-looking statements appearing in this document except as may be required by law.

SOURCE Prologis, Inc.